- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 19, Issue 8, 2012
Current Medicinal Chemistry - Volume 19, Issue 8, 2012
Volume 19, Issue 8, 2012
-
-
Editorial [Hot Topic: Recent Achievements on G-Protein Coupled Receptors (Guest Editor: Slawomir Filipek)]
More LessTwo important breakthroughs, in crystallography and in molecular simulations, moved forward investigations of the G-protein coupled receptors (GPCRs). Based on the recent crystal structures of GPCRs with agonists, and also on the results from very long simulations exceeding the microsecond frontier, it was possible to answer the fundamental questions about their multiple activation schemes in anticipation of a m Read More
-
-
-
Action of Molecular Switches in GPCRs - Theoretical and Experimental Studies
Authors: B. Trzaskowski, D. Latek, S. Yuan, U. Ghoshdastider, A. Debinski and S. FilipekG protein coupled receptors (GPCRs), also called 7TM receptors, form a huge superfamily of membrane proteins that, upon activation by extracellular agonists, pass the signal to the cell interior. Ligands can bind either to extracellular N-terminus and loops (e.g. glutamate receptors) or to the binding site within transmembrane helices (Rhodopsin-like family). They are all activated by agonists although a spontaneous auto Read More
-
-
-
Evolution of Class A G-Protein-Coupled Receptors: Implications for Molecular Modeling
Authors: M. Chabbert, H. Castel, J. Pele, J. Deville, R. Legendre and P. RodienClass A or rhodopsin-like G-protein-coupled receptors (GPCRs) constitute the largest transmembrane receptor family of the human genome. Because of their biological and pharmaceutical importance, the evolutionary history of these receptors has been widely studied. Most studies agree on the classification of the 700 members of this family into a dozen of sub-families. However, the relationship between these sub-familie Read More
-
-
-
Crosstalk within GPCR Heteromers in Schizophrenia and Parkinson's Disease: Physical or Just Functional?
Authors: R. Guixa-Gonzalez, A. Bruno, M. Marti-Solano and J. SelentCrosstalk between G protein-coupled receptors (GPCRs) is one of the key mechanisms used by the cell for integrating multiple signaling pathways. Functional crosstalk at the level of signaling pathways was initially thought to regulate receptor function. Importantly, the existence of GPCR heteromers demonstrates that direct physical interactions between GPCRs could also be behind the crosstalk phenomenon. Neurologica Read More
-
-
-
A Closer Look into G Protein Coupled Receptor Activation: X-Ray Crystallography and Long-Scale Molecular Dynamics Simulations
Authors: S. Vanni and U. RothlisbergerG protein coupled receptors (GPCRs) are a large eukaryotic protein family of transmembrane receptors that react to a signal coming from the extracellular environment to generate an intracellular response through the activation of a signal transduction pathway mediated by a heterotrimeric G protein. Their diversity, dictated by the multiplicity of stimuli to which they respond and by the variety of intracellular si Read More
-
-
-
Ensemble of G Protein-Coupled Receptor Active States
More LessG protein-coupled receptors (GPCRs) play critical roles in cellular signal transduction and are important targets for therapeutics. Although these receptors have been intensely studied for quite some time, our understanding about their mechanism of action is still incomplete. GPCR activity has traditionally been viewed within the context of two-state models where the receptor is in equilibrium between a single inactive state and Read More
-
-
-
Recent Progress in Understanding of Structure, Ligand Interactions and the Mechanism of Activation of the β 2-Adrenergic Receptor
Authors: M. Kolinski, A. Plazinska and K. JozwiakThe understanding of β2-adrenergic receptor (β2AR) interactions with ligands as well as the mechanism of receptor activation changed radically from 2007, when the first crystallographic structure of the receptor was reported. Since then numerous crystallographic studies described interactions with all main classes of β2AR ligands and with G proteins, which provided a great insight into the molecular structure of the Read More
-
-
-
RAS/RAF/MEK Inhibitors in Oncology
Authors: P. Rusconi, E. Caiola and M. BrogginiThe RAS/RAF/MEK signaling pathway plays a central role in mediating both proliferation and survival of cancer cells. These proteins are a group of serine/threonine kinases activated in response to a variety of extracellular stimuli and mediate signal transduction from the cell surface towards both nuclear and cytosolic targets. In combination with several other signaling pathways, they can differentially alter phosphorylation sta Read More
-
-
-
Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Authors: K. D. Beare, M. J. Coster and P. J. RutledgeHIV-1 integrase is one of the three viral enzymes essential to HIV replication. Consequently the development of therapeutics targeting this enzyme has been a major focus of antiretroviral research over the past two decades. Several classes of integrase inhibitors have been identified; of these the diketoacids (DKAs) show greatest promise: raltegravir (Merck & Co) has been approved by the US Food and Drug Administration (FD Read More
-
-
-
Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Authors: G. Siasos, D. Tousoulis, C. Kollia, E. Oikonomou, Z. Siasou, C. Stefanadis and A. G. PapavassiliouAdiponectin is an abundant plasma protein secreted from adipocytes. Its role in energy homeostasis is well-known, including the regulation of hydrocarbons and lipids metabolism as well as the improvement of insulin resistance. It has been thought to be a key molecule in the development of type 2 diabetes mellitus and metabolic syndrome, which are epidemiological targets for preventing cardiovascular disease. In additio Read More
-
-
-
New Developments in the Diagnosis and Management of Resistant Hypertension
Authors: A. Oliveras and A. de la SierraArterial hypertension is a well-known disease with a worldwide high prevalence and impaired prognosis with respect to normotensive subjects, due to increased cardiovascular mortality and morbidity. Blood pressure levels over range can be successfully controlled with adequate treatment, but more than 10% of hypertensive people have their blood pressure uncontrolled despite a therapeutic regimen of 3 or more antihyperten Read More
-
-
-
Molecular Pathways Involved in the Early and Late Damage Induced by Testis Ischemia: Evidence for a Rational Pharmacological Modulation
Authors: D. Altavilla, C. Romeo, F. Squadrito, H. Marini, G. Morgia, P. Antonuccio and L. MinutoliTesticular torsion or torsion of the spermatic cord is a surgical emergency in which misdiagnosis and inappropriate treatment can lead to male infertility. Events occurring during testicular torsion and detorsion are representative of an ischemia-reperfusion injury observed in other organs. The two most important factors determining testicular damage are the degree of twisting and the early onset of a surgical treatment to Read More
-
-
-
Advances in the Research of β-Ketoacyl-ACP Synthase III (FabH) Inhibitors
Authors: H. -J. Zhang, Z. -L. Li and H. -L. ZhuFatty acid biosynthesis is essential for bacterial survival. In recent years, components of this biosynthetic pathway have aroused wide concern. β-Ketoacyl-acyl carrier protein synthase III (FabH) is a particularly attractive target which catalyzes the initial step of fatty acid biosynthesis. In this review, fatty acid biosynthesis, recent advances in the research of FabH as well as related inhibitors are reviewed. Finally, we also discus Read More
-
-
-
Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Authors: G. L. Beretta, V. Zuco, P. Perego and N. ZaffaroniDNA topoisomerase I is required for DNA relaxation during a variety of cellular functions. The identification of camptothecins as specific enzyme poisons and their clinical efficacy have stimulated extensive efforts to exploit topoisomerase I as a therapeutic target for cancer. However, several limitations of camptothecins, such as low solubility and stability, high toxicity, and the occurrence of resistance, have encouraged the de Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
